(CNN) In a rare move, the companies that make the multiple sclerosis drug daclizumab (brand name Zinbryta) have voluntarily pulled the medication from the market and stopped all clinical studies after reports of eight cases of serious brain inflammation among patients in Europe. Manufacturers Biogen and AbbVie acted on the same day the European Medicines Agency called for an " urgent review " of the multiple sclerosis medicine. Multiple sclerosis is a neurological disease that affects more than 2.3 million people worldwide, according to the National Multiple Sclerosis Society. The European Medicines Agency said it will contact doctors directly in the next few days. The European Medicines Agency added that patients on daclizumab are advised not to stop their medication without consulting their doctor.

Source: CNN March 02, 2018 23:03 UTC